JP6840222B2 - clec14aに特異的に結合する脱糖化抗体及びその用途 - Google Patents
clec14aに特異的に結合する脱糖化抗体及びその用途 Download PDFInfo
- Publication number
- JP6840222B2 JP6840222B2 JP2019503563A JP2019503563A JP6840222B2 JP 6840222 B2 JP6840222 B2 JP 6840222B2 JP 2019503563 A JP2019503563 A JP 2019503563A JP 2019503563 A JP2019503563 A JP 2019503563A JP 6840222 B2 JP6840222 B2 JP 6840222B2
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- cancer
- light chain
- heavy chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000033115 angiogenesis Effects 0.000 claims description 53
- 206010028980 Neoplasm Diseases 0.000 claims description 43
- 230000027455 binding Effects 0.000 claims description 35
- 230000015572 biosynthetic process Effects 0.000 claims description 30
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 27
- 201000011510 cancer Diseases 0.000 claims description 25
- 239000000427 antigen Substances 0.000 claims description 24
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 208000023275 Autoimmune disease Diseases 0.000 claims description 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 206010009944 Colon cancer Diseases 0.000 claims description 13
- 206010052428 Wound Diseases 0.000 claims description 10
- 208000027418 Wounds and injury Diseases 0.000 claims description 10
- 206010025323 Lymphomas Diseases 0.000 claims description 9
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 9
- 208000029742 colonic neoplasm Diseases 0.000 claims description 9
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 9
- 201000002528 pancreatic cancer Diseases 0.000 claims description 9
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 239000012634 fragment Substances 0.000 claims description 8
- 208000003445 Mouth Neoplasms Diseases 0.000 claims description 7
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims description 7
- 201000007270 liver cancer Diseases 0.000 claims description 7
- 208000014018 liver neoplasm Diseases 0.000 claims description 7
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 5
- 206010014733 Endometrial cancer Diseases 0.000 claims description 5
- 206010014759 Endometrial neoplasm Diseases 0.000 claims description 5
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 5
- 206010038389 Renal cancer Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 5
- 201000010982 kidney cancer Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 210000004185 liver Anatomy 0.000 claims description 5
- 230000004770 neurodegeneration Effects 0.000 claims description 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 5
- 201000000849 skin cancer Diseases 0.000 claims description 5
- 201000002510 thyroid cancer Diseases 0.000 claims description 5
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 208000018084 Bone neoplasm Diseases 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 4
- 206010057644 Testis cancer Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000005787 hematologic cancer Diseases 0.000 claims description 4
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims description 4
- 208000031209 hemophilic arthropathy Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 201000005202 lung cancer Diseases 0.000 claims description 4
- 208000020816 lung neoplasm Diseases 0.000 claims description 4
- 201000008006 pharynx cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000003120 testicular cancer Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 208000003732 Cat-scratch disease Diseases 0.000 claims description 3
- 206010011017 Corneal graft rejection Diseases 0.000 claims description 3
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 3
- 206010056474 Erythrosis Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 206010061218 Inflammation Diseases 0.000 claims description 3
- 208000002260 Keloid Diseases 0.000 claims description 3
- 206010023330 Keloid scar Diseases 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 3
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims description 3
- 206010038934 Retinopathy proliferative Diseases 0.000 claims description 3
- 206010043515 Throat cancer Diseases 0.000 claims description 3
- 208000025865 Ulcer Diseases 0.000 claims description 3
- 208000002495 Uterine Neoplasms Diseases 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 238000005469 granulation Methods 0.000 claims description 3
- 230000004054 inflammatory process Effects 0.000 claims description 3
- 210000001117 keloid Anatomy 0.000 claims description 3
- 230000009401 metastasis Effects 0.000 claims description 3
- 201000003142 neovascular glaucoma Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 208000037803 restenosis Diseases 0.000 claims description 3
- 230000009885 systemic effect Effects 0.000 claims description 3
- 231100000397 ulcer Toxicity 0.000 claims description 3
- 206010046766 uterine cancer Diseases 0.000 claims description 3
- 230000002792 vascular Effects 0.000 claims description 3
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 49
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 43
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 35
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 34
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 34
- 230000000694 effects Effects 0.000 description 32
- 229960000397 bevacizumab Drugs 0.000 description 28
- 230000001404 mediated effect Effects 0.000 description 20
- 230000001419 dependent effect Effects 0.000 description 19
- 238000000034 method Methods 0.000 description 19
- 238000002965 ELISA Methods 0.000 description 18
- 238000011282 treatment Methods 0.000 description 17
- 238000003556 assay Methods 0.000 description 16
- 210000004204 blood vessel Anatomy 0.000 description 16
- 210000002889 endothelial cell Anatomy 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 229940120638 avastin Drugs 0.000 description 12
- 238000001727 in vivo Methods 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 11
- 230000005012 migration Effects 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 239000013641 positive control Substances 0.000 description 11
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 10
- 230000003511 endothelial effect Effects 0.000 description 10
- 108010082117 matrigel Proteins 0.000 description 10
- 235000000346 sugar Nutrition 0.000 description 10
- 102000001554 Hemoglobins Human genes 0.000 description 9
- 108010054147 Hemoglobins Proteins 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000002776 aggregation Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 230000001772 anti-angiogenic effect Effects 0.000 description 9
- 230000036252 glycation Effects 0.000 description 9
- 229960000470 omalizumab Drugs 0.000 description 9
- 210000003556 vascular endothelial cell Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000004520 agglutination Effects 0.000 description 8
- 238000004220 aggregation Methods 0.000 description 8
- 230000009260 cross reactivity Effects 0.000 description 8
- 229940099073 xolair Drugs 0.000 description 8
- 241000282412 Homo Species 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 230000002860 competitive effect Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 101000942280 Homo sapiens C-type lectin domain family 14 member A Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 108091008605 VEGF receptors Proteins 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 230000001988 toxicity Effects 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 230000005747 tumor angiogenesis Effects 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 102000018358 immunoglobulin Human genes 0.000 description 5
- 238000000126 in silico method Methods 0.000 description 5
- 238000005457 optimization Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 102100032556 C-type lectin domain family 14 member A Human genes 0.000 description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 4
- 241001529936 Murinae Species 0.000 description 4
- 239000002870 angiogenesis inducing agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000010534 mechanism of action Effects 0.000 description 4
- 210000004088 microvessel Anatomy 0.000 description 4
- 238000002823 phage display Methods 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 3
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 3
- 108050009406 C-type lectin-like Proteins 0.000 description 3
- 102000002086 C-type lectin-like Human genes 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 208000032612 Glial tumor Diseases 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000699660 Mus musculus Species 0.000 description 3
- 101100439860 Mus musculus Clec14a gene Proteins 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 3
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 3
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 3
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 3
- 229960002964 adalimumab Drugs 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 230000012292 cell migration Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 229940048921 humira Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 230000003908 liver function Effects 0.000 description 3
- 238000010232 migration assay Methods 0.000 description 3
- 238000011580 nude mouse model Methods 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 102000001301 EGF receptor Human genes 0.000 description 2
- 108060006698 EGF receptor Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 206010061309 Neoplasm progression Diseases 0.000 description 2
- KPKZJLCSROULON-QKGLWVMZSA-N Phalloidin Chemical compound N1C(=O)[C@@H]([C@@H](O)C)NC(=O)[C@H](C)NC(=O)[C@H](C[C@@](C)(O)CO)NC(=O)[C@H](C2)NC(=O)[C@H](C)NC(=O)[C@@H]3C[C@H](O)CN3C(=O)[C@@H]1CSC1=C2C2=CC=CC=C2N1 KPKZJLCSROULON-QKGLWVMZSA-N 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000009227 antibody-mediated cytotoxicity Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000007541 cellular toxicity Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 201000010918 connective tissue cancer Diseases 0.000 description 2
- 230000030944 contact inhibition Effects 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000010005 growth-factor like effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 102000050373 human CLEC14A Human genes 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000011532 immunohistochemical staining Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000004001 molecular interaction Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000005084 renal tissue Anatomy 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 229960005314 suramin Drugs 0.000 description 2
- FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 230000005751 tumor progression Effects 0.000 description 2
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 2
- 210000003606 umbilical vein Anatomy 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 239000003799 water insoluble solvent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 description 1
- ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)N1CC2=C(CC1)NN=N2 ZRPAUEVGEGEPFQ-UHFFFAOYSA-N 0.000 description 1
- JVKRKMWZYMKVTQ-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]pyrazol-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C=1C=NN(C=1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JVKRKMWZYMKVTQ-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108090000342 C-Type Lectins Proteins 0.000 description 1
- 102000003930 C-Type Lectins Human genes 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 102100024649 Cell adhesion molecule 1 Human genes 0.000 description 1
- 241000252505 Characidae Species 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 1
- 102220560149 DENN domain-containing protein 2B_S34G_mutation Human genes 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100026236 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVRNDRQMDRJTHS-CBQIKETKSA-N N-Acetyl-D-Galactosamine Chemical compound CC(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@H](O)[C@@H]1O OVRNDRQMDRJTHS-CBQIKETKSA-N 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N N-acetyl-D-galactosamine Natural products CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010009711 Phalloidine Proteins 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000012288 TUNEL assay Methods 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 238000008050 Total Bilirubin Reagent Methods 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 1
- 102220559237 Voltage-dependent L-type calcium channel subunit alpha-1C_N32R_mutation Human genes 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 229940121369 angiogenesis inhibitor Drugs 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 229940125644 antibody drug Drugs 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- -1 aromatics Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000012575 bio-layer interferometry Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 101150004928 bun gene Proteins 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 101150036876 cre gene Proteins 0.000 description 1
- 210000004292 cytoskeleton Anatomy 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000006325 deglycation Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 231100001135 endothelial toxicity Toxicity 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 102000057041 human TNF Human genes 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004692 intercellular junction Anatomy 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 201000004962 larynx cancer Diseases 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000009149 molecular binding Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- INAAIJLSXJJHOZ-UHFFFAOYSA-N pibenzimol Chemical compound C1CN(C)CCN1C1=CC=C(N=C(N2)C=3C=C4NC(=NC4=CC=3)C=3C=CC(O)=CC=3)C2=C1 INAAIJLSXJJHOZ-UHFFFAOYSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
- 108700038288 rhodamine-phalloidin Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 238000013042 tunel staining Methods 0.000 description 1
- 230000006444 vascular growth Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Description
配列番号3の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号4の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号5の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号25の重鎖CDR3、
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号37の重鎖CDR3、又は
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号40の重鎖CDR3を含むことができる。
配列番号8の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号9の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号10の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号7の軽鎖可変領域及び配列番号61の重鎖可変領域、
配列番号7の軽鎖可変領域及び配列番号73の重鎖可変領域、又は
配列番号7の軽鎖可変領域及び配列番号76の重鎖可変領域を含むことができる。
ncer)、咽頭癌(pharynx cancer)、喉頭癌(larynx cancer)、肺癌(lung cancer)、結腸癌(colon cancer)、乳癌(breast cancer)、子宮頸癌(uterine cervical cancer)、子宮内膜癌(endometrial cancer)、卵巣癌(ovarian cancer)、前立腺癌(prostate cancer)、睾丸癌(testis cancer)、膀胱癌(bladder cancer)、腎臓癌(renal cancer)、肝癌(liver cancer)、膵癌(pancreatic cancer)、骨癌(bone cancer)、結合組織癌(connective tissue cancer)、皮膚癌(skin cancer)、脳腫瘍(brain cancer)、甲状腺癌(thyroid cancer)、白血病(leukemia)、ホジキンリンパ腫(Hodgkin’s lymphoma)、リンパ腫(lymphoma)及び多発性骨髄血液癌(multiple myeloid blood cancer)で構成された群から選ばれるが、これに限定されるものではない。
WO2013/187556において、clec14a−CTLD親抗体がin vitroで特異的に血管新生特性を調節し得ることを報告したことがある。ただし、親抗体(WO2013/187556のクローン1)の場合、精製過程で凝集が著しく起きることを確認し、抗体収率向上のための追加最適化過程が必要だった。このため、in silicoベースのCDRグラフトを行った。親抗体の重鎖及び軽鎖可変領域内の6個のCDR(表1)をFDA承認された治療用抗体4種(adalimumab(humira(登録商標))、omalizumab(Xolair(登録商標))、tratuzumab(herceptin(登録商標))、bevacizumab(avastin(登録商標)))のそれぞれのフレームワーク部位にグラフトした(図1A)。
治療用蛋白質における糖化異質性はバイオ医薬品の開発及び生産において特性品質に重要な影響を及ぼし得る。in silicoベースのクローン1 IgGの糖化評価によってクローン1 IgGの軽鎖CDR1内の推定的なN−糖化部位を確認した。このような予想されるN−糖化部位を除去するために、N−糖化部位に無作為変異を有する半合成抗体ライブラリーを作製し、脱糖化工程を行った。具体的に、NNKトリヌクレオシドオリゴヌクレオシドでランダム化された半合成scFv(single chain variable fragment)を作製し、磁性ビーズのコートされたヒト及びマウスclec14a−CTLDを含むファージディスプレイ技術を用いて連続的にバイオパンニングを行った。最後に、選別されたscFvクローンのDNAをシーケンシングした後、ヒト及びマウスclec14a−CTLDs(hclec14a−CTLD及びmclec14a−CTLD)の両方に強く反応する4種のクローン及び予想N−糖化部位から、異なるアミノ酸配列を無作為的に選択した(図2A)。
Deglyco C1 IgGのclec14a−CTLD結合位置を確認するために、HRP(horseradish peroxidase)がコンジュゲーションされたdeglyco C1 IgG(deglyco C1 IgG−HRP)を作製した後、競合ELISAを実施した。
血管新生においてdeglyco C1 IgGの作用機作を確認するために、野生型clec14aで形質感染され、親抗体IgG又はdeglyco C1 IgGの存在又は不在下で培養されたHEK293F細胞を用いて、形成された細胞凝集体の数をモニタし、clec14a媒介細胞−細胞接触に対する機能的アッセイを行った。
内皮細胞毒性に対するdeglyco C1 IgGの影響を評価するために、deglyco C1 IgG処理後にHUVECs生存度を測定した。生存度はCell Counting Kit−8(#CK04−13,Dojindo Laboratories,Kumamoto,Japan)を用いてメーカーのマニュアルに従って測定した。
Deglyco C1 IgGのVEGF依存的血管新生に対するin vitro効果を確認するために、deglyco C1 IgGの存在又は不在下でHUVECsをVEGFで処理した後、HUVECチューブ形成アッセイを行った。150μlのマトリゲル(Matrigel)を48ウェルプレートに入れて、30分間37℃でインキュベーションした。EGM−2で培養されたHUVEC(105)を収穫し、マトリゲルのコートされたプレートに接種し、クローン1 IgG、親抗体IgG、脱糖化clec14a−CTLD IgG又はベバシズマブの存在又は不在下で、37℃で18時間インキュベーションした。VEGF含むEBM(endothelial cell basal medium)で培養されたHUVECsを、マトリゲルのコートされたプレートに接種し、deglyco C1 IgG(20μg ml−1)の存在又は不在下で、37℃で18時間インキュベーションした。
腫瘍血管新生においてclec14aの連関性を確認するために、まず、SNU182ヒト肝細胞又はCFPAC−1ヒト膵癌細胞癌腫を含む異種移植腫瘍モデル(xenograft tumor models)を確立し、clec14a及び公知の内皮マーカー蛋白質であるCD31に対する商業的に入手可能な抗体を用いて免疫組織化学を行った。免疫組織化学は0.1%(w/v)ゼラチンコートされたガラスカバースリップで成長したHUVECs(5X104)をdeglyco C1 IgGの存在又は不在下で、24時間37℃でインキュベーションした。4%(w/v)PFAで細胞を固定させ、1時間37℃で5%(w/v)BSA及び0.1%(v/v)Triton X−100を含むPBSで遮断した後、ローダミンファロイジン(1unit/well)及びHoechst33258染色薬で1時間インキュベーションした。
実施例8−1.最適化リード抗体の選別
追加最適化抗体を選別するために、抗体36種をさらに選別し、deglyco C1に比べて親和度が改善された抗体を選別した。表5の36種の抗体(IgG抗体形態)が含まれたほ乳動物発現ベクターを、それぞれPEI(polyethylenimine)を用いてHEK293細胞に形質感染後、7日間40mlずつ培養した。遠心分離を用いて培養液を得た後、蛋白質A親和度クロマトグラフィー(affinity column chromatography with protein A sepharose column)によって精製した。SDS−PAGEを用いて90%の精製度を確認し、軽鎖及び重鎖の分子量を同時に確認した(図8A)。
血管新生の主要因子のVEGF依存性血管新生(VEGF−dependent angiogenesis)に対する最適化リード抗体の血管新生抑制能を確認するために、実時間血管新生分析が可能なIncuCyte FLR live content imaging system(Essen Bioscience Inc)を用いて抗血管新生能を比較分析した。まず、GFP−形質感染されたHUVECを94ウェルプレートに撒いて36種の抗体を20ug/mlの濃度で処理し、in vitro効能を比較した。この時、parental IgG(親抗体:WO2013/187556のクローン1)、deglyco C1及びベバシズマブ(avastin)を陽性対照群として使用して最適化抗体との効能を比較分析した。
選別された抗体の抗原結合部位を確認するために競合ELISA(competition ELISA)を行った。具体的に、まずCTLD抗原を96ウェルマイクロタイタープレートにコートし、HRP−接合されたdeglyco C1 IgGと結合を誘導した(図14A)。同時にそれぞれの36種の抗体を処理し、deglyco C1と競合的に抗原に結合するかどうかを確認することによってdeglyco C1 IgGと36種抗体の抗原結合部位を確認した。その結果を図14Bに示しており、全36種の抗体はdeglyco C1 IgGと類似の抗原結合部位を有することが確認できた。
最適化抗体の種間交差反応性(cross−species reactivitiy)を確認するために、HUVEC(human umbilical vein endothelial cell)とMAEC(mouse aortic endothelial cell)をそれぞれ培養し、両細胞に20ug/ml親抗体(original C1)、deglyco C1、クローン1、13、16をそれぞれ処理して、両細胞表面に結合能があるかを、流細胞分析機(flow cytometry)を用いて確認した。その結果を図15に示した。結論的に、最適化抗体の3種クローン1、13、16はヒト及びネズミCLEC14aに結合し得る種間交差反応性があることを確認した。
最適化抗体の作用機転分析のためにまず、最適化抗体の血管内皮細胞の細胞−細胞接合阻害能を確認した。本出願の発明者等は血管内皮細胞の細胞−細胞接合にCLEC14aにおいて特にCTLDドメインが重要な役割を担うことと、CLEC14−CTLD結合抗体(original C1)がそれらの相互作用阻害剤としての役割を担うことを明らかにしたことがある(図16A)。
本発明は一態様において、以下を提供する。
(項目1)
clec14aに特異的に結合する抗体であって、
TGSSSNIGXXXVT(配列番号1)のCDR1を含む軽鎖可変領域を含み、
配列番号1の9番目、10番目及び11番目位置のアミノ酸Xのそれぞれは、R、C、G、A、T、W、S、N、Vで構成された群から選ばれるいずれか一つであることを特徴とする抗体。
(項目2)
前記配列番号1の9番目、10番目及び11番目位置のアミノ酸は、RCG、ATA、WSN又はAVVであることを特徴とする、項目1に記載の抗体。
(項目3)
脱糖化されたことを特徴とする、項目1に記載の抗体。
(項目4)
配列番号21〜24で構成された群から選ばれる一つ以上のフレームワーク部位を含む軽鎖可変領域を含むことを特徴とする、項目1に記載の抗体。
(項目5)
配列番号7〜10で構成された群から選ばれる軽鎖可変領域を含むことを特徴とする、項目1に記載の抗体。
(項目6)
配列番号13、25〜60で構成された群から選ばれるCDR3を含む重鎖可変領域を含むことを特徴とする、項目1に記載の抗体。
(項目7)
配列番号6、61〜96で構成された群から選ばれる重鎖可変領域を含むことを特徴とする、項目1に記載の抗体。
(項目8)
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号3の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号4の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号5の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3、
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号25の重鎖CDR3、
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号37の重鎖CDR3、又は
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号40の重鎖CDR3を含むことを特徴とする、項目1に記載の抗体。
(項目9)
配列番号7の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号8の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号9の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号10の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号7の軽鎖可変領域及び配列番号61の重鎖可変領域、
配列番号7の軽鎖可変領域及び配列番号73の重鎖可変領域、又は
配列番号7の軽鎖可変領域及び配列番号76の重鎖可変領域を含むことを特徴とする、項目1に記載の抗体。
(項目10)
項目1〜9のいずれかに記載の抗体を含む、血管新生関連疾患の予防又は治療用薬学的組成物。
(項目11)
前記血管新生関連疾患は、癌、転移(metastasis)、糖尿病網膜症(diabetic retinopathy)、未熟児網膜症(retinopathy of prematurity)、角膜移植拒否(corneal graft rejection)、黄斑変性(macular degeneration)、血管新生緑内障(neovascular glaucoma)、全身紅皮症(erythrosis)、増殖性網膜症(proliferative retinopathy)、乾癬(psoriasis)、血友病性股関節炎(hemophilic arthritis)、動脈硬化性プラーク(atherosclerotic plaques)の毛細血管形成、ケロイド(keloid)、傷顆粒化(wound granulation)、血管癒着(vascular adhesion)、リューマチ関節炎(rheumatoid arthritis)、退行性関節炎(osteoarthritis)、自己免疫疾患(autoimmune diseases)、クローン病(Crohn’s d
isease)、レステノシス(restenosis)、粥状動脈硬化症(atherosclerosis)、腸狭窄(intestinal adhesions)、猫ひっかき病(cat scratch disease)、潰瘍(ulcer)、肝硬変症(liver cirrhosis)、腎臓炎(nephritis)、糖尿病性腎臓疾患(diabetic nephropathy)、真性糖尿病(diabetes mellitus)、炎症疾患(inflammatory diseases)及び神経変性疾患(neurodegenerative diseases)で構成された群から選ばれることを特徴とする、項目10に記載の組成物。
(項目12)
前記癌は、食道癌(esophageal cancer)、胃癌(stomach cancer)、大腸癌(large intestine cancer)、直膓癌(rectal cancer)、口腔癌(oral cancer)、咽頭癌(pharynx cancer)、喉頭癌(larynx cancer)、肺癌(lung cancer)、結腸癌(colon cancer)、乳癌(breast cancer)、子宮頸癌(uterine cervical cancer)、子宮内膜癌(endometrial cancer)、卵巣癌(ovarian cancer)、前立腺癌(prostate cancer)、睾丸癌(testis cancer)、膀胱癌(bladder cancer)、腎臓癌(renal cancer)、肝癌(liver cancer)、膵癌(pancreatic cancer)、骨癌(bone cancer)、結合組織癌(connective tissue cancer)、皮膚癌(skin cancer)、脳腫瘍(brain cancer)、甲状腺癌(thyroid cancer)、白血病(leukemia)、ホジキンリンパ腫(Hodgkin’s lymphoma)、リンパ腫(lymphoma)及び
多発性骨髄血液癌(multiple myeloid blood cancer)で構成された群から選ばれることを特徴とする、項目11に記載の組成物。
Claims (9)
- clec14aに特異的に結合する抗体またはその抗原結合断片であって、
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号13の重鎖CDR3;
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号25の重鎖CDR3;
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号37の重鎖CDR3;または
配列番号2の軽鎖CDR1、配列番号15の軽鎖CDR2及び配列番号16の軽鎖CDR3、配列番号11の重鎖CDR1、配列番号12の重鎖CDR2及び配列番号40の重鎖CDR3を含むことを特徴とする抗体。 - 脱糖化されたことを特徴とする、請求項1に記載の抗体またはその抗原結合断片。
- 前記抗体が配列番号21〜24で構成された群から選ばれる一つ以上のフレームワーク部位を含む軽鎖可変領域を含むことを特徴とする、請求項1に記載の抗体またはその抗原結合断片。
- 前記抗体が配列番号7の軽鎖可変領域を含むことを特徴とする、請求項1に記載の抗体またはその抗原結合断片。
- 前記抗体が配列番号6、61、73および76で構成された群から選ばれる重鎖可変領域を含むことを特徴とする、請求項1に記載の抗体またはその抗原結合断片。
- 前記抗体が
配列番号7の軽鎖可変領域及び配列番号6の重鎖可変領域、
配列番号7の軽鎖可変領域及び配列番号61の重鎖可変領域、
配列番号7の軽鎖可変領域及び配列番号73の重鎖可変領域、又は
配列番号7の軽鎖可変領域及び配列番号76の重鎖可変領域を含むことを特徴とする、請求項1に記載の抗体またはその抗原結合断片。 - 請求項1〜6のいずれかに記載の抗体またはその抗原結合断片を含む、血管新生関連疾患の予防又は治療用薬学的組成物。
- 前記血管新生関連疾患は、癌、転移(metastasis)、糖尿病網膜症(diabetic retinopathy)、未熟児網膜症(retinopathy of prematurity)、角膜移植拒否(corneal graft rejection)、黄斑変性(macular degeneration)、血管新生緑内障(neovascular glaucoma)、全身紅皮症(erythrosis)、増殖性網膜症(proliferative retinopathy)、乾癬(psoriasis)、血友病性股関節炎(hemophilic arthritis)、動脈硬化性プラーク(atherosclerotic plaques)の毛細血管形成、ケロイド(keloid)、傷顆粒化(wound granulation)、血管癒着(vascular adhesion)、リューマチ関節炎(rheumatoid arthritis)、退行性関節炎(osteoarthritis)、自己免疫疾患(autoimmune diseases)、クローン病(Crohn’s d
isease)、レステノシス(restenosis)、粥状動脈硬化症(atherosclerosis)、腸狭窄(intestinal adhesions)、猫ひっかき病(cat scratch disease)、潰瘍(ulcer)、肝硬変症(liver cirrhosis)、腎臓炎(nephritis)、糖尿病性腎臓疾患(diabetic nephropathy)、真性糖尿病(diabetes mellitus)、炎症疾患(inflammatory diseases)及び神経変性疾患(neurodegenerative diseases)で構成された群から選ばれることを特徴とする、請求項7に記載の組成物。 - 前記癌は、食道癌(esophageal cancer)、胃癌(stomach cancer)、大腸癌(large intestine cancer)、直膓癌(rectal cancer)、口腔癌(oral cancer)、咽頭癌(pharynx cancer)、喉頭癌(larynx cancer)、肺癌(lung cancer)、結腸癌(colon cancer)、乳癌(breast cancer)、子宮頸癌(uterine cervical cancer)、子宮内膜癌(endometrial cancer)、卵巣癌(ovarian cancer)、前立腺癌(prostate cancer)、睾丸癌(testis cancer)、膀胱癌(bladder cancer)、腎臓癌(renal cancer)、肝癌(liver cancer)、膵癌(pancreatic cancer)、骨癌(bone cancer)、結合組織癌(connective tissue cancer)、皮膚癌(skin cancer)、脳腫瘍(brain cancer)、甲状腺癌(thyroid cancer)、白血病(leukemia)、ホジキンリンパ腫(Hodgkin’s lymphoma)、リンパ腫(lymphoma)及び
多発性骨髄血液癌(multiple myeloid blood cancer)で構成された群から選ばれることを特徴とする、請求項8に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160115577 | 2016-09-08 | ||
KR10-2016-0115577 | 2016-09-08 | ||
PCT/KR2017/009851 WO2018048234A1 (ko) | 2016-09-08 | 2017-09-08 | clec14a에 특이적으로 결합하는 탈당화 항체 및 그 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019534844A JP2019534844A (ja) | 2019-12-05 |
JP6840222B2 true JP6840222B2 (ja) | 2021-03-10 |
Family
ID=61562361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019503563A Active JP6840222B2 (ja) | 2016-09-08 | 2017-09-08 | clec14aに特異的に結合する脱糖化抗体及びその用途 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20190309074A1 (ja) |
EP (1) | EP3511341A4 (ja) |
JP (1) | JP6840222B2 (ja) |
KR (1) | KR102201992B1 (ja) |
CN (1) | CN110312735A (ja) |
AU (1) | AU2017322783B2 (ja) |
CA (1) | CA3035723A1 (ja) |
WO (1) | WO2018048234A1 (ja) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070042360A1 (en) * | 2001-09-17 | 2007-02-22 | Eos Biotechnology, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
US7534427B2 (en) * | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
JP5095416B2 (ja) * | 2005-12-06 | 2012-12-12 | 協和発酵キリン株式会社 | 抗perp遺伝子組換え抗体 |
WO2010047509A2 (ko) * | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 dr5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
KR101224468B1 (ko) * | 2009-05-20 | 2013-01-23 | 주식회사 파멥신 | 신규한 형태의 이중표적항체 및 그 용도 |
ES2567030T3 (es) | 2009-09-03 | 2016-04-19 | Cancer Research Technology Limited | Inhibidores de CLEC14A |
WO2013187556A1 (en) * | 2012-06-14 | 2013-12-19 | Scripps Korea Antibody Institute | Novel antibody specific for clec14a and uses thereof |
-
2017
- 2017-09-08 CN CN201780050176.XA patent/CN110312735A/zh active Pending
- 2017-09-08 EP EP17849118.9A patent/EP3511341A4/en not_active Withdrawn
- 2017-09-08 CA CA3035723A patent/CA3035723A1/en not_active Abandoned
- 2017-09-08 US US16/319,037 patent/US20190309074A1/en not_active Abandoned
- 2017-09-08 JP JP2019503563A patent/JP6840222B2/ja active Active
- 2017-09-08 WO PCT/KR2017/009851 patent/WO2018048234A1/ko unknown
- 2017-09-08 KR KR1020197004877A patent/KR102201992B1/ko active IP Right Grant
- 2017-09-08 AU AU2017322783A patent/AU2017322783B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2019534844A (ja) | 2019-12-05 |
AU2017322783A1 (en) | 2019-03-28 |
KR20190026925A (ko) | 2019-03-13 |
EP3511341A4 (en) | 2020-05-13 |
US20190309074A1 (en) | 2019-10-10 |
CN110312735A (zh) | 2019-10-08 |
EP3511341A1 (en) | 2019-07-17 |
CA3035723A1 (en) | 2018-03-15 |
KR102201992B1 (ko) | 2021-01-12 |
AU2017322783B2 (en) | 2020-04-30 |
WO2018048234A1 (ko) | 2018-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4620591B2 (ja) | ヒトインスリン様成長因子に対する遺伝子組換え抗体 | |
JP2023538782A (ja) | Ccr8抗体及びその用途 | |
EA035947B1 (ru) | Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo | |
CN109988240B (zh) | 抗gpc-3抗体及其用途 | |
US11820831B2 (en) | Antibody binding to carbonic anhydrase and use thereof | |
KR101589135B1 (ko) | 인간화 항-emapii 항체 및 이의 용도 | |
JP2019531762A (ja) | Vegfに対する合成の抗体およびそれらの使用 | |
JP6840222B2 (ja) | clec14aに特異的に結合する脱糖化抗体及びその用途 | |
CN114667296B (zh) | 一种双特异性抗体及其用途 | |
US20230036655A1 (en) | Anti-gdf15 antibody | |
JP2019050737A (ja) | Cd44陽性tmem−180陽性のがん細胞由来微粒子、これを用いた抗tmem−180抗体療法が有効ながん患者の選別方法、選別された患者に対する抗tmem−180抗体を含む抗がん剤、および前記方法に用いるキット | |
CN114437227A (zh) | 双特异抗体及其应用 | |
US11028178B2 (en) | Method of treating nonalcoholic steatohepatitis by administering an antagonist human tumor necrosis factor receptor 1 (HUTNFR1) antibody | |
EP4349861A1 (en) | Bispecific binding molecule binding vegf and ang2 and use thereof | |
WO2021190437A1 (en) | Antibodies against areg and its use | |
RU2773819C2 (ru) | Белок, связанный с гликопротеином человека, композиция, фармацевтическая композиция, вектор экспрессии | |
EA044106B1 (ru) | АНТИ-huTNFR1 ТЕРАПИЯ НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТА | |
CN118043350A (en) | Bispecific antibodies against VEGF A and VEGF C and uses thereof | |
KR20130135869A (ko) | 항 단쇄 제4형 콜라겐 폴리펩타이드 항체 및 이를 포함하는 종양의 진단, 예방 또는 치료용 약제 | |
CA3044216A1 (en) | Antibody specifically binding to pauf protein and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190314 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200814 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210126 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210216 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6840222 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |